Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer
Xilio Therapeutics (Nasdaq: XLO) has appointed Caroline Hensley as chief legal officer. Hensley joins from Seres Therapeutics, where she served as senior vice president, assistant general counsel and chief compliance officer, overseeing corporate legal and compliance matters. Her experience includes managing capital markets transactions, clinical development activities, commercial launches, and FDA regulatory compliance. Previously, she worked as a corporate associate at Latham & Watkins, representing biotechnology companies in various transactions. Hensley holds a B.A. in economics from the University of Texas at Austin and a J.D. from Boston University School of Law.
Xilio Therapeutics (Nasdaq: XLO) ha nominato Caroline Hensley come responsabile legale. Hensley arriva da Seres Therapeutics, dove ha ricoperto il ruolo di vicepresidente senior, avvocato generale assistente e responsabile della conformità, supervisionando questioni legali aziendali e di conformità. La sua esperienza include la gestione di transazioni nei mercati capitali, attività di sviluppo clinico, lanci commerciali e conformità alle normative della FDA. In precedenza, ha lavorato come associato aziendale presso Latham & Watkins, rappresentando aziende biotecnologiche in varie transazioni. Hensley ha conseguito una laurea in economia presso l'Università del Texas ad Austin e un J.D. presso la Boston University School of Law.
Xilio Therapeutics (Nasdaq: XLO) ha nombrado a Caroline Hensley como directora legal. Hensley llega de Seres Therapeutics, donde se desempeñó como vicepresidenta senior, asistente del consejero general y oficial principal de cumplimiento, supervisando asuntos legales y de cumplimiento corporativo. Su experiencia incluye la gestión de transacciones en los mercados de capitales, actividades de desarrollo clínico, lanzamientos comerciales y cumplimiento regulatorio con la FDA. Anteriormente, trabajó como asociada corporativa en Latham & Watkins, representando a empresas de biotecnología en diversas transacciones. Hensley tiene una licenciatura en economía de la Universidad de Texas en Austin y un J.D. de la Facultad de Derecho de la Universidad de Boston.
Xilio Therapeutics (Nasdaq: XLO)가 Caroline Hensley를 법률 최고 책임자로 임명했습니다. Hensley는 Seres Therapeutics에서 선임 부사장, 수석 법무 보좌관 및 최고 준수 책임자로 재직하며 기업 법률 및 준수 문제를 감독했습니다. 그녀의 경험에는 자본 시장 거래, 임상 개발 활동, 상업적 출시 및 FDA 규제 준수 관리가 포함됩니다. 이전에는 Latham & Watkins에서 기업 변호사로 일하며 다양한 거래에서 생명공학 회사를 대표했습니다. Hensley는 텍사스 대학교 오스틴 캠퍼스에서 경제학 학사 학위를 받고 보스턴 대학교 로스쿨에서 J.D.를 취득했습니다.
Xilio Therapeutics (Nasdaq: XLO) a nommé Caroline Hensley au poste de directrice juridique. Hensley rejoint Seres Therapeutics, où elle occupait le poste de vice-présidente senior, avocate générale adjointe et responsable de la conformité, supervisant les questions juridiques et de conformité de l'entreprise. Son expérience comprend la gestion des transactions sur les marchés des capitaux, les activités de développement clinique, les lancements commerciaux et le respect des réglementations de la FDA. Auparavant, elle a travaillé comme associée en droit des affaires chez Latham & Watkins, représentant des entreprises de biotechnologie dans diverses transactions. Hensley est titulaire d'une licence en économie de l'Université du Texas à Austin et d'un J.D. de la Boston University School of Law.
Xilio Therapeutics (Nasdaq: XLO) hat Caroline Hensley zur Leiterin der Rechtsabteilung ernannt. Hensley kommt von Seres Therapeutics, wo sie als Senior Vice President, stellvertretende General Counsel und Chief Compliance Officer tätig war und die rechtlichen und compliancebezogenen Angelegenheiten des Unternehmens überwachte. Zu ihrer Erfahrung gehört die Verwaltung von Transaktionen im Kapitalmarkt, klinischen Entwicklungsaktivitäten, kommerziellen Markteinführungen und die Einhaltung der Vorschriften der FDA. Zuvor arbeitete sie als Corporate Associate bei Latham & Watkins, wo sie Biotechnologieunternehmen in verschiedenen Transaktionen vertrat. Hensley hat einen B.A. in Wirtschaftswissenschaften von der University of Texas at Austin und einen J.D. von der Boston University School of Law.
- Strengthened executive team with experienced legal leadership
- Addition of expertise in capital markets, clinical development, and FDA compliance
- Enhanced capabilities in managing commercial launch activities and partnerships
- None.
WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Caroline (Holda) Hensley as chief legal officer.
“Caroline is an accomplished lawyer and biotechnology executive who brings a wealth of experience advising public life science companies across all stages of development and commercialization,” said René Russo, Pharm.D., president and chief executive officer of Xilio. “Her expertise and strategic insights make her a tremendous addition to our executive team, and we are excited to have her onboard.”
Ms. Hensley most recently served as senior vice president, assistant general counsel and chief compliance officer at Seres Therapeutics, Inc., where she oversaw all corporate legal and compliance matters, including capital markets and licensing transactions, clinical development and commercial launch activities, partnership/collaboration management, and FDA and healthcare regulatory compliance matters. Previously, Ms. Hensley was a corporate associate in the Boston office of Latham & Watkins, where she represented public and private companies in biotechnology and other industries across a range of capital markets and strategic transactions throughout their lifecycle. She received her B.A. in economics from the University of Texas at Austin and her J.D. from the Boston University School of Law.
“I am thrilled to join the Xilio team at this pivotal moment in the company's growth and look forward to helping to advance Xilio’s promising pipeline of novel, tumor-activated immuno-oncology therapies,” said Ms. Hensley.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecifics and immune cell engagers. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
Investor and Media Contact
Scott Young
Vice President, Investor Relations and Corporate Communications
investors@xiliotx.com
FAQ
Who is the new chief legal officer at Xilio Therapeutics (XLO)?
What was Caroline Hensley's previous role before joining XLO?
What are Caroline Hensley's key areas of expertise for XLO?
What is Caroline Hensley's educational background?
